接受黑色素瘤脑转移放射外科治疗患者的预后指数比较
该研究分析了422例连续接受伽玛刀立体定向放射外科治疗的黑色素瘤脑转移患者(共1440个脑转移灶),比较RPA、SIR、BSBM和DS-GPA四种预后指数对生存期的预测。结果显示DS-GPA指数在各分级间病例数最均衡,且对总生存期的预后判断最佳。
要点
- DS-GPA指数在各分级间病例数最均衡,对总生存期的预后判断最佳。
- RPA分级III、II、I级生存期分别为2.6、5.5、13.0个月。
- DS-GPA评分≥2.5的患者放射外科治疗后生存期可预期改善。
核心结论
- DS-GPA指数被证明对接受放射外科治疗的黑色素瘤脑转移患者最均衡且对生存期最具预测性。
- DS-GPA评分≥2.5的患者放射外科治疗后生存期可预期改善。
研究设计与样本
- 回顾性分析422例连续接受伽玛刀立体定向放射外科治疗的黑色素瘤脑转移患者(共1440个脑转移灶)。
- 中位全脑肿瘤体积为4.7 cm³(范围0.3-69.3 cm³),中位转移灶数目为2个(范围1-32)。
- 132例患者接受了全脑放射治疗。
- 采用RPA、SIR、BSBM和DS-GPA四种预后指数比较生存期。
主要发现
- RPA指数:III级(n=27)生存期2.6个月,II级(n=348)5.5个月,I级(n=47)13.0个月。
- DS-GPA指数:评分0-1(n=67)生存期2.8个月,评分1.5-2.0(n=143)4.2个月,评分2.5-3.0(n=111)6.6个月,评分3.5-4.0(n=101)9.4个月。
- SIR指数:评分0-3(n=56)生存期3.2个月,评分4-7(n=319)5.8个月,评分8-10(n=47)12.7个月。
- BSBM指数:BSBM0(n=47)生存期2.6个月,BSBM1(n=282)5.4个月,BSBM2(n=86)11.0个月,BSBM3(n=7)8.8个月。
- DS-GPA指数在各分级间病例数最均衡,且对总生存期的预后判断总体最佳。
临床怎么用
- 作者认为DS-GPA指数对接受放射外科治疗的黑色素瘤脑转移患者最均衡且对生存期最具预测性。
- 作者指出DS-GPA评分≥2.5的患者放射外科治疗后生存期可预期改善。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE The goal of this study was to use 4 prognostic indices to compare survival times of patients who underwent Gamma Knife stereotactic radiosurgery (SRS) to treat melanoma brain metastases. METHODS The authors analyzed 422 consecutive patients (1440 brain metastases) who underwent Gamma Knife SRS. The median total brain tumor volume was 4.7 cm3 (range 0.3-69.3 cm3), and the median number of metastases was 2 (range 1-32). One hundred thirty-two patients underwent whole-brain radiation therapy. Survival times were compared using recursive partitioning analysis (RPA), the Score Index for Radiosurgery (SIR), the Basic Score for Brain Metastases (BSBM), and the Diagnosis-Specific Graded Prognostic Assessment (DS-GPA). RESULTS The overall survival times after SRS were compared. With the RPA index, survival times were 2.6 months (Class III, n = 27), 5.5 months (Class II, n = 348), and 13.0 months (Class I, n = 47). With the DS-GPA index, survival times were 2.8 months (Scores 0-1, n = 67), 4.2 months (Scores 1.5-2.0, n = 143), 6.6 months (Scores 2.5-3.0, n = 111), and 9.4 months (Scores 3.5-4.0, n = 101). With the SIR, survival times were 3.2 months (Scores 0-3, n = 56), 5.8 months (Scores 4-7, n = 319), and 12.7 months (Scores 8-10, n = 47). With the BSBM index, survival times were 2.6 months (BSBM0, n = 47), 5.4 months (BSBM1, n = 282), 11.0 months (BSBM2, n = 86), and 8.8 months (BSBM3, n = 7). The DS-GPA index was the most balanced by case numbers in each class and provided the overall best prognostic index for overall survival. CONCLUSIONS The DS-GPA index proved most balanced and predictive of survival for patients with melanoma who underwent SRS as part of management for brain metastases. Patients whose DS-GPA score was ≥ 2.5 had predictably improved survival times after SRS.
引用
- Kano H, Morales-Restrepo A, Iyer A, et al. Comparison of prognostic indices in patients who undergo melanoma brain metastasis radiosurgery. J Neurosurg. 2017. PMID: 28106495. doi:10.3171/2016.9.JNS161011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。